Glis2 and Ccnd1 Expression Levels in Breast Cancer Patients

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

Glis2 and Ccnd1 Expression Levels in Breast Cancer Patients Publisher Pubmed

Sadeghi M¹ ; Gholizadeh M² ; Safataj N^{3, 4} ; Tahmasebivand M⁵ ; Mohajeri G⁶ ; Lotfi H⁷ ; Bostanabad SY⁸ ; Safar B¹ ; Salehi M^{9, 10}

Show Affiliations

1. Department of Genetics, Faculty of Science, Shahrekord University, Shahrekord, Iran
2. Department of Hematology and Blood Banking, Faculty of Allied Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Department of Genetics, Islamic Azad University, Shahrekord Branch, Shahrekord, Iran
4. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
5. Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
6. Department of Surgery, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
7. Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran
8. Department of Pharmacology, Faculty of Pharmacy, Istanbul Health and Technology University, Istanbul, Turkey
9. Cellular, Molecular and Genetics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
10. Medical Genetics Research Center of Genome, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Breast Disease Published:2023

Abstract

Breast cancer (BC) is the most prevalent cancer in women, with increasing incidence and death rates in recent years. Disruptions of different signaling pathways partially cause breast cancer. Hence, different genes through particular pathways are involved in BC tumorigenesis. METHODS: In this study, we evaluated the expression level of GLIS2 and CCND1 genes in 50 patients. Also, in-silico analyses were used to enrich related signaling pathways involving the mentioned genes. RESULTS: The results showed an increased expression level of Cyclin D1 and decreased expression level of GLIS2 in BC patients. Moreover, a relationship between aberrant expression levels of GLIS2 and CCND1 and BC development was determined. CONCLUSION: These observations could help uncover new therapeutic targets for treating patients with BC in the progressive stage. © 2023 - IOS Press. All rights reserved.

Related Docs

View other Related Docs

1. Role of Cyclin D1 in Breast Carcinoma, Journal of Research in Medical Sciences (2013)

2. Therapeutic Potential of Plk1, Kif4a, Cdca5, Ube2c, Cdt1, Ska3, Aurkb, and Pttg1 Genes in Triple-Negative Breast Cancer: Correlating Their Expression With Sensitivity to Gsk 461364 and Ikk 16 Drugs, Biochemical Genetics (2024)

3. Prognostic Significance of Chek2 Mutation in Progression of Breast Cancer, Lab Medicine (2019)

4. Determinants of Prognosis in Triple-Negative Breast Cancer: Report From a Large Breast Cancer Registry, Archives of Iranian Medicine (2021)

5. A Comprehensive Insight Into the Correlation Between Ncrnas and the Wnt/Β-Catenin Signalling Pathway in Gastric Cancer Pathogenesis, Cell Communication and Signaling (2023)

6. The Landscape of Exosomal Non-Coding Rnas in Breast Cancer Drug Resistance, Focusing on Underlying Molecular Mechanisms, Frontiers in Pharmacology (2023)

7. Anticancer Activity of Britannin Through the Downregulation of Cyclin D1 and Cdk4 in Human Breast Cancer Cells, Journal of Cancer Research and Therapeutics (2019)

8. Cancer Vaccines As a Targeted Immunotherapy Approach for Breast Cancer: An Update of Clinical Evidence, Expert Review of Vaccines (2022)

Experts (# of related papers)

View all Related Experts

Mahmoud Aghaei (5)

Mojtaba Panjehpour (4)

Other Related Docs

9. Multifaceted Role of Vitamin D in Breast Cancer: A Systematic Review of Genetic and Pathway-Based Mechanisms, Asian Pacific Journal of Cancer Prevention (2024)

10. Mir-195 Down-Regulation Is a Distinctive Biomarker of Her2 Positive State in Breast Cancer, Gene Reports (2020)

11. The Role of P130cas/Bcar1 Adaptor Protein in the Pathogenesis of Cardiovascular Diseases: A Literature Review, American Heart Journal Plus: Cardiology Research and Practice (2024)

12. Therapeutic Opportunities in Breast Cancer by Targeting Macrophage Migration Inhibitory Factor As a Pleiotropic Cytokine, Breast Cancer: Basic and Clinical Research (2024)

13. A3 Adenosine Receptor Agonist Inhibited Survival of Breast Cancer Stem Cells Via Gli-1 and Erk1/2 Pathway, Journal of Cellular Biochemistry (2017)

14. Interactions Dietary Components With Expression Level of Breast Cancer-Related Genes, Egyptian Journal of Medical Human Genetics (2022)

15. Cancer-Associated Fibroblasts Regulate the Plasticity of Breast Cancer Stemness Through the Production of Leukemia Inhibitory Factor, Life (2021)

16. Dna Methylation and Microrna Patterns Are in Association With the Expression of Brca1 in Ovarian Cancer, Cellular and Molecular Biology (2016)

17. Leukemia Inhibitory Factor: A Main Controller of Breast Cancer, Journal of Biosciences (2020)

18. Gene Expression Profiles of Cyp24a1 and Cyp27b1 in Malignant and Normal Breast Tissues, Molecular Medicine Reports (2017)

19. Comparative Expression of Breast Cancer 1 Tumor Suppressor Protein in Cancerous and Healthy Colorectal Specimens, Journal of Isfahan Medical School (2016)

20. Mini Review: The Fda-Approved Prescription Drugs That Target the Mapk Signaling Pathway in Women With Breast Cancer, Breast Disease (2021)

21. A2b Adenosine Receptor Agonist Induces Cell Cycle Arrest and Apoptosis in Breast Cancer Stem Cells Via Erk1/2 Phosphorylation, Cellular Oncology (2018)

22. Synergistic Antitumor Effect of Nvp-Bez235 and Cape on Mda-Mb-231 Breast Cancer Cells, Biomedicine and Pharmacotherapy (2017)

23. In Silico Identification and in Vitro Evaluation of Mrps30-Dt Lncrna and Mrps30 Gene Expression in Breast Cancer, Cancer Reports (2024)

24. Genomic Rearrangement Screening of the Brca1 From Seventy Iranian High-Risk Breast Cancer Families, Journal of Research in Medical Sciences (2016)

25. Discordance of Human Epidermal Growth Factor Receptor-2 Expression in Primary Breast Cancer and Related Axillary Lymph Node Metastasis, Asian Journal of Pharmaceutics (2018)

26. Expression and Clinicopathological Significance of Lipin-1 in Human Breast Cancer and Its Association With P53 Tumor Suppressor Gene, Journal of Cellular Physiology (2020)

27. Ggcn Polymorphism of Erf3a/Gspt1 Gene and Breast Cancer Susceptibility, Medical Oncology (2012)

28. P16 Expression in Human Breast Carcinoma and Its Relationship to Clinicopathological Parameters, Advanced Biomedical Research (2023)

29. Comparison of the Structural, Cytological and Biomarker Expression in Carcinoma in Situ and Invasive Components in Breast Carcinoma, Iranian Journal of Pathology (2024)

30. An Immunohistochemistry Study of Tissue Bcl-2 Expression and Its Serum Levels in Breast Cancer Patients, Annals of the New York Academy of Sciences (2008)

31. Apoptosis and Cell Cycle Regulatory Effects of Adenosine by Modulation of Gli-1 and Erk1/2 Pathways in Cd44+ and Cd24− Breast Cancer Stem Cells, Cell Proliferation (2017)

32. Comprehensive Analysis of the Prognostic Value of Glutathione S-Transferases Mu Family Members in Breast Cancer, Cell Biology International (2024)

33. The Upregulation of Hsa-Mir-181B-1 and Downregulation of Its Target Cyld in the Late-Stage of Tumor Progression of Breast Cancer, Indian Journal of Clinical Biochemistry (2020)

34. Identification of Significant Genes and Pathways Associated With Tenascin-C in Cancer Progression by Bioinformatics Analysis, Advanced Biomedical Research (2022)

35. Molecular Mechanism of Apoptosis Induction by Gaillardin, a Sesquiterpene Lactone, in Breast Cancer Cell Lines: Gaillardin-Induced Apoptosis in Breast Cancer Cell Lines, Cell Biology and Toxicology (2015)

36. Evaluation of the Association Between Centrosome Amplification in Tumor Tissue of Breast Cancer Patients and Changes in the Expression of Cetn1 and Cntrob Genes, Gene Reports (2022)

37. Deregulation of Mir-1245B-5P and Mir-92A-3P and Their Potential Target Gene, Gata3, in Epithelial–Mesenchymal Transition Pathway in Breast Cancer, Cancer Reports (2024)

38. Integrated Analysis of Transcriptome and Epigenome Reveals Ensr00000272060 As a Potential Biomarker in Gastric Cancer, Epigenomics (2024)

Style	Citing Format
MLA	Sadeghi M, et al.. "Glis2 and Ccnd1 Expression Levels in Breast Cancer Patients." Breast Disease, vol. 42, no. 1, 2023, pp. 251-259.
APA	Sadeghi M, Gholizadeh M, Safataj N, Tahmasebivand M, Mohajeri G, Lotfi H, Bostanabad SY, Safar B, Salehi M (2023). Glis2 and Ccnd1 Expression Levels in Breast Cancer Patients. Breast Disease, 42(1), 251-259.
Chicago	Sadeghi M, Gholizadeh M, Safataj N, Tahmasebivand M, Mohajeri G, Lotfi H, Bostanabad SY, Safar B, Salehi M. "Glis2 and Ccnd1 Expression Levels in Breast Cancer Patients." Breast Disease 42, no. 1 (2023): 251-259.
Harvard	Sadeghi M et al. (2023) 'Glis2 and Ccnd1 Expression Levels in Breast Cancer Patients', Breast Disease, 42(1), pp. 251-259.
Vancouver	Sadeghi M, Gholizadeh M, Safataj N, Tahmasebivand M, Mohajeri G, Lotfi H, et al.. Glis2 and Ccnd1 Expression Levels in Breast Cancer Patients. Breast Disease. 2023;42(1):251-259.
BibTex	@article{ author = {Sadeghi M and Gholizadeh M and Safataj N and Tahmasebivand M and Mohajeri G and Lotfi H and Bostanabad SY and Safar B and Salehi M}, title = {Glis2 and Ccnd1 Expression Levels in Breast Cancer Patients}, journal = {Breast Disease}, volume = {42}, number = {1}, pages = {251-259}, year = {2023} }
RIS	TY - JOUR AU - Sadeghi M AU - Gholizadeh M AU - Safataj N AU - Tahmasebivand M AU - Mohajeri G AU - Lotfi H AU - Bostanabad SY AU - Safar B AU - Salehi M TI - Glis2 and Ccnd1 Expression Levels in Breast Cancer Patients JO - Breast Disease VL - 42 IS - 1 SP - 251 EP - 259 PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract